ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Fostemsavir addresses a critical need for those with little to no treatment options left who are at risk of further disease progression